利用 SEER-Medicare 数据集对 IV 期乳腺癌长期存活者进行预测建模。

IF 4.5 2区 医学 Q1 ONCOLOGY
Cancers Pub Date : 2024-12-01 DOI:10.3390/cancers16234033
Nabil Adam, Robert Wieder
{"title":"利用 SEER-Medicare 数据集对 IV 期乳腺癌长期存活者进行预测建模。","authors":"Nabil Adam, Robert Wieder","doi":"10.3390/cancers16234033","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Treatment of women with stage IV breast cancer (BC) extends population-averaged survival by only a few months. Here, we develop a model for identifying individual circumstances where appropriate therapy will extend survival while minimizing adverse events.</p><p><strong>Objective: </strong>Our goal is to develop high-confidence deep learning (DL) models to predict survival in individual stage IV breast cancer patients based on their unique circumstances generated by patient, cancer, treatment, and adverse event variables. We previously showed that predictive DL survival modeling of potentially curable stage I-III patients can be improved by combining time-fixed and time-varying covariates. Here, we demonstrate that DL-based predictive survival modeling in stage IV patients, where treatment does not offer a cure, can generate accurate individual survival predictions by considering subsequent lines of potential treatment to guide therapy. This guidance is rarely obtainable in the nearly limitless scenarios of metastatic disease.</p><p><strong>Design, setting, and participants: </strong>We applied the SEER-Medicare linked dataset from 1991 to 2016 to investigate 14,312 unique stage IV patients with 1,880,153 entries. We used DeepSurv- and DeepHit-, Nnet-survival- and Cox-Time DL-based predictive models to consider the combination of time-fixed and time-varying covariates at each visit for each patient. We adopted random sampling to divide the input dataset into training, validation, and testing sets. We verified the models' implementation using the pycox package and fine-tuned the models using the open-source library Amazon SageMaker Python SDK 2.232.2 (software development kit). Our results demonstrated the proof of principle of the models by generating individual patients' survival curves.</p><p><strong>Conclusions and relevance: </strong>By extending the survival prediction models to consider stage IV BC patients' time-fixed and time-varying covariates, we achieved a prediction error below 10%. Based on their circumstance-specific situations, these models can predict survival in individual stage IV patients with high confidence. The models will serve as an important adjunct to treatment decisions in patients with stage IV BC and test what-if scenarios of treatment or no treatment options to optimize therapy for extending patient lives and minimizing adverse events.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 23","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predictive Modeling of Long-Term Survivors with Stage IV Breast Cancer Using the SEER-Medicare Dataset.\",\"authors\":\"Nabil Adam, Robert Wieder\",\"doi\":\"10.3390/cancers16234033\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Importance: </strong>Treatment of women with stage IV breast cancer (BC) extends population-averaged survival by only a few months. Here, we develop a model for identifying individual circumstances where appropriate therapy will extend survival while minimizing adverse events.</p><p><strong>Objective: </strong>Our goal is to develop high-confidence deep learning (DL) models to predict survival in individual stage IV breast cancer patients based on their unique circumstances generated by patient, cancer, treatment, and adverse event variables. We previously showed that predictive DL survival modeling of potentially curable stage I-III patients can be improved by combining time-fixed and time-varying covariates. Here, we demonstrate that DL-based predictive survival modeling in stage IV patients, where treatment does not offer a cure, can generate accurate individual survival predictions by considering subsequent lines of potential treatment to guide therapy. This guidance is rarely obtainable in the nearly limitless scenarios of metastatic disease.</p><p><strong>Design, setting, and participants: </strong>We applied the SEER-Medicare linked dataset from 1991 to 2016 to investigate 14,312 unique stage IV patients with 1,880,153 entries. We used DeepSurv- and DeepHit-, Nnet-survival- and Cox-Time DL-based predictive models to consider the combination of time-fixed and time-varying covariates at each visit for each patient. We adopted random sampling to divide the input dataset into training, validation, and testing sets. We verified the models' implementation using the pycox package and fine-tuned the models using the open-source library Amazon SageMaker Python SDK 2.232.2 (software development kit). Our results demonstrated the proof of principle of the models by generating individual patients' survival curves.</p><p><strong>Conclusions and relevance: </strong>By extending the survival prediction models to consider stage IV BC patients' time-fixed and time-varying covariates, we achieved a prediction error below 10%. Based on their circumstance-specific situations, these models can predict survival in individual stage IV patients with high confidence. The models will serve as an important adjunct to treatment decisions in patients with stage IV BC and test what-if scenarios of treatment or no treatment options to optimize therapy for extending patient lives and minimizing adverse events.</p>\",\"PeriodicalId\":9681,\"journal\":{\"name\":\"Cancers\",\"volume\":\"16 23\",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/cancers16234033\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers16234033","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Predictive Modeling of Long-Term Survivors with Stage IV Breast Cancer Using the SEER-Medicare Dataset.

Importance: Treatment of women with stage IV breast cancer (BC) extends population-averaged survival by only a few months. Here, we develop a model for identifying individual circumstances where appropriate therapy will extend survival while minimizing adverse events.

Objective: Our goal is to develop high-confidence deep learning (DL) models to predict survival in individual stage IV breast cancer patients based on their unique circumstances generated by patient, cancer, treatment, and adverse event variables. We previously showed that predictive DL survival modeling of potentially curable stage I-III patients can be improved by combining time-fixed and time-varying covariates. Here, we demonstrate that DL-based predictive survival modeling in stage IV patients, where treatment does not offer a cure, can generate accurate individual survival predictions by considering subsequent lines of potential treatment to guide therapy. This guidance is rarely obtainable in the nearly limitless scenarios of metastatic disease.

Design, setting, and participants: We applied the SEER-Medicare linked dataset from 1991 to 2016 to investigate 14,312 unique stage IV patients with 1,880,153 entries. We used DeepSurv- and DeepHit-, Nnet-survival- and Cox-Time DL-based predictive models to consider the combination of time-fixed and time-varying covariates at each visit for each patient. We adopted random sampling to divide the input dataset into training, validation, and testing sets. We verified the models' implementation using the pycox package and fine-tuned the models using the open-source library Amazon SageMaker Python SDK 2.232.2 (software development kit). Our results demonstrated the proof of principle of the models by generating individual patients' survival curves.

Conclusions and relevance: By extending the survival prediction models to consider stage IV BC patients' time-fixed and time-varying covariates, we achieved a prediction error below 10%. Based on their circumstance-specific situations, these models can predict survival in individual stage IV patients with high confidence. The models will serve as an important adjunct to treatment decisions in patients with stage IV BC and test what-if scenarios of treatment or no treatment options to optimize therapy for extending patient lives and minimizing adverse events.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancers
Cancers Medicine-Oncology
CiteScore
8.00
自引率
9.60%
发文量
5371
审稿时长
18.07 days
期刊介绍: Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信